Skip to content

Study · Other design · 2024

9 results

Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.

Osumili B, Fan L, Paik JS, Pantalone KM, Ranta K, Sapin H, Tofé S

Diabetes research and clinical practice21 May 2024Cited by 2 (Europe PMC)

PMID38777128 (opens in a new tab)DOI10.1016/j.diabres.2024.111717 (opens in a new tab)PepBankPUB-38777128
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanOther designEfficacy outcome

    In adults with type 2 diabetes on metformin, all tirzepatide doses reduced HbA1c significantly more than semaglutide 0.5 mg by week 40 in an indirect comparison.

    In plain wordsIn an indirect comparison, all tirzepatide doses lowered HbA1c more than semaglutide 0.5 mg in adults with type 2 diabetes.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c reduction versus semaglutide 0.5 mg
    Study

    n: not reported in source

    Comparator
    Semaglutide 0.5 mg (indirect comparison)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    All tirzepatide doses showed statistically significantly greater reductions in glycated haemoglobin, body weight and body mass index from baseline to week 40, with a comparable adverse event (AE) profile and no statistically significant differences in the odds of gastrointestinal AEs versus semaglutide 0.5 mg.
    1 context sentence
    Summary · context
    The aITCs were performed using the Bucher method to compare the relative efficacy and safety of tirzepatide 5, 10 and 15 mg versus semaglutide 0.5 mg via a common comparator (subcutaneous semaglutide 1.0 mg) based on trial results from SURPASS-2 (NCT03987919) and SUSTAIN7 (NCT02648204).
  2. 02HumanOther designEfficacy outcome

    In adults with type 2 diabetes on metformin, all tirzepatide doses reduced body weight significantly more than semaglutide 0.5 mg by week 40 in an indirect comparison.

    In plain wordsIn an indirect comparison, all tirzepatide doses led to more weight loss than semaglutide 0.5 mg in adults with type 2 diabetes.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight reduction versus semaglutide 0.5 mg
    Study

    n: not reported in source

    Comparator
    Semaglutide 0.5 mg (indirect comparison)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    All tirzepatide doses showed statistically significantly greater reductions in glycated haemoglobin, body weight and body mass index from baseline to week 40, with a comparable adverse event (AE) profile and no statistically significant differences in the odds of gastrointestinal AEs versus semaglutide 0.5 mg.
    1 context sentence
    Summary · context
    The aITCs were performed using the Bucher method to compare the relative efficacy and safety of tirzepatide 5, 10 and 15 mg versus semaglutide 0.5 mg via a common comparator (subcutaneous semaglutide 1.0 mg) based on trial results from SURPASS-2 (NCT03987919) and SUSTAIN7 (NCT02648204).
  3. 03HumanOther designEfficacy outcome

    In adults with type 2 diabetes on metformin, all tirzepatide doses reduced body mass index significantly more than semaglutide 0.5 mg by week 40 in an indirect comparison.

    In plain wordsIn an indirect comparison, all tirzepatide doses lowered BMI more than semaglutide 0.5 mg in adults with type 2 diabetes.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBMI reduction versus semaglutide 0.5 mg
    Study

    n: not reported in source

    Comparator
    Semaglutide 0.5 mg (indirect comparison)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    All tirzepatide doses showed statistically significantly greater reductions in glycated haemoglobin, body weight and body mass index from baseline to week 40, with a comparable adverse event (AE) profile and no statistically significant differences in the odds of gastrointestinal AEs versus semaglutide 0.5 mg.
    1 context sentence
    Summary · context
    The aITCs were performed using the Bucher method to compare the relative efficacy and safety of tirzepatide 5, 10 and 15 mg versus semaglutide 0.5 mg via a common comparator (subcutaneous semaglutide 1.0 mg) based on trial results from SURPASS-2 (NCT03987919) and SUSTAIN7 (NCT02648204).
  4. 04HumanOther designSafety outcome

    In the indirect comparison, tirzepatide doses had a comparable adverse event profile to semaglutide 0.5 mg.

    In plain wordsIn an indirect comparison, tirzepatide and semaglutide 0.5 mg had a similar side effect profile.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAdverse event profile
    Study

    n: not reported in source

    Comparator
    Semaglutide 0.5 mg (indirect comparison)
    Outcome group
    Adverse events · Whole body
    Studied dose
    5, 10 and 15 mg · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    with a comparable adverse event (AE) profile and no statistically significant differences in the odds of gastrointestinal AEs versus semaglutide 0.5 mg.
    1 context sentence
    Summary · context
    The aITCs were performed using the Bucher method to compare the relative efficacy and safety of tirzepatide 5, 10 and 15 mg versus semaglutide 0.5 mg via a common comparator (subcutaneous semaglutide 1.0 mg) based on trial results from SURPASS-2 (NCT03987919) and SUSTAIN7 (NCT02648204).
  5. 05HumanOther designSafety outcome

    In the indirect comparison, there were no statistically significant differences in the odds of gastrointestinal adverse events between tirzepatide doses and semaglutide 0.5 mg.

    In plain wordsIn an indirect comparison, tirzepatide and semaglutide 0.5 mg did not differ significantly in stomach and gut side effects.

    Peptide
    Tirzepatide
    Outcome
    No significant changeGastrointestinal adverse events
    Study

    n: not reported in source

    Comparator
    Semaglutide 0.5 mg (indirect comparison)
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    5, 10 and 15 mg · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    no statistically significant differences in the odds of gastrointestinal AEs versus semaglutide 0.5 mg.
    1 context sentence
    Summary · context
    The aITCs were performed using the Bucher method to compare the relative efficacy and safety of tirzepatide 5, 10 and 15 mg versus semaglutide 0.5 mg via a common comparator (subcutaneous semaglutide 1.0 mg) based on trial results from SURPASS-2 (NCT03987919) and SUSTAIN7 (NCT02648204).
  6. 06HumanOther designEfficacy outcome

    All tirzepatide doses showed greater odds of reaching an HbA1c of 6.5 % or less versus semaglutide 0.5 mg in the indirect comparison.

    In plain wordsIn an indirect comparison, people on tirzepatide were more likely than those on semaglutide 0.5 mg to reach an HbA1c of 6.5% or less.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHbA1c target of 6.5 % or less
    Study

    n: not reported in source

    Comparator
    Semaglutide 0.5 mg (indirect comparison)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    all tirzepatide doses showed greater odds of patients achieving HbA1c targets of ≤ 6.5 % (≤48 mmol/mol) and < 7.0 % (<53 mmol/mol)
    1 context sentence
    Summary · context
    The aITCs were performed using the Bucher method to compare the relative efficacy and safety of tirzepatide 5, 10 and 15 mg versus semaglutide 0.5 mg via a common comparator (subcutaneous semaglutide 1.0 mg) based on trial results from SURPASS-2 (NCT03987919) and SUSTAIN7 (NCT02648204).
  7. 07HumanOther designEfficacy outcome

    All tirzepatide doses showed greater odds of reaching an HbA1c below 7.0 % versus semaglutide 0.5 mg in the indirect comparison.

    In plain wordsIn an indirect comparison, people on tirzepatide were more likely than those on semaglutide 0.5 mg to reach an HbA1c below 7.0%.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHbA1c target below 7.0 %
    Study

    n: not reported in source

    Comparator
    Semaglutide 0.5 mg (indirect comparison)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    all tirzepatide doses showed greater odds of patients achieving HbA1c targets of ≤ 6.5 % (≤48 mmol/mol) and < 7.0 % (<53 mmol/mol)
    1 context sentence
    Summary · context
    The aITCs were performed using the Bucher method to compare the relative efficacy and safety of tirzepatide 5, 10 and 15 mg versus semaglutide 0.5 mg via a common comparator (subcutaneous semaglutide 1.0 mg) based on trial results from SURPASS-2 (NCT03987919) and SUSTAIN7 (NCT02648204).
  8. 08HumanOther designEfficacy outcome

    All tirzepatide doses showed greater odds of reaching weight loss of 5 % or more versus semaglutide 0.5 mg in the indirect comparison.

    In plain wordsIn an indirect comparison, people on tirzepatide were more likely than those on semaglutide 0.5 mg to lose 5% or more of body weight.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight loss of 5 % or more
    Study

    n: not reported in source

    Comparator
    Semaglutide 0.5 mg (indirect comparison)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    Furthermore, all tirzepatide doses showed greater odds of patients achieving HbA1c targets of ≤ 6.5 % (≤48 mmol/mol) and < 7.0 % (<53 mmol/mol) and weight loss targets of ≥ 5 % and ≥ 10 %, versus semaglutide 0.5 mg.
    1 context sentence
    Summary · context
    The aITCs were performed using the Bucher method to compare the relative efficacy and safety of tirzepatide 5, 10 and 15 mg versus semaglutide 0.5 mg via a common comparator (subcutaneous semaglutide 1.0 mg) based on trial results from SURPASS-2 (NCT03987919) and SUSTAIN7 (NCT02648204).
  9. 09HumanOther designEfficacy outcome

    All tirzepatide doses showed greater odds of reaching weight loss of 10 % or more versus semaglutide 0.5 mg in the indirect comparison.

    In plain wordsIn an indirect comparison, people on tirzepatide were more likely than those on semaglutide 0.5 mg to lose 10% or more of body weight.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight loss of 10 % or more
    Study

    n: not reported in source

    Comparator
    Semaglutide 0.5 mg (indirect comparison)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    Furthermore, all tirzepatide doses showed greater odds of patients achieving HbA1c targets of ≤ 6.5 % (≤48 mmol/mol) and < 7.0 % (<53 mmol/mol) and weight loss targets of ≥ 5 % and ≥ 10 %, versus semaglutide 0.5 mg.
    1 context sentence
    Summary · context
    The aITCs were performed using the Bucher method to compare the relative efficacy and safety of tirzepatide 5, 10 and 15 mg versus semaglutide 0.5 mg via a common comparator (subcutaneous semaglutide 1.0 mg) based on trial results from SURPASS-2 (NCT03987919) and SUSTAIN7 (NCT02648204).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03987919

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

Eli Lilly and Companyn = 1,87930 Jul 2019 to 15 Feb 2021

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 14 Feb 2022
CompletedPhase 3Results postedNCT02648204

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Novo Nordisk A/Sn = 1,2016 Jan 2016 to 19 May 2017

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 15 Oct 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.